图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 2.156 5年影响因子: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukaryotGeneExpr.2017019712
pages 229-236

Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus

Kanwal Rehman
Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
Muhammad Sajid Hamid Akash
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
Aamira Liaqat
Department of Pharmaceutical Chemistry, Government College University Faisalabad, Pakistan; Department of Biochemistry, Government College University Faisalabad, Pakistan
Shagufta Kamal
Department of Biochemistry, Government College University Faisalabad, Pakistan
Muhammad Imran Qadir
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
Akhtar Rasul
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan

ABSTRACT

Interleukin-6 (IL-6) is a proinflammatory cytokine that decisively induces the development of insulin resistance and pathogenesis of type 2 diabetes mellitus (T2DM) through the generation of inflammation by controlling differentiation, migration, proliferation, and cell apoptosis. The presence of IL-6 in tissues is a normal consequence, but its irregular production and long-term exposure leads to the development of inflammation, which induces insulin resistance and overt T2DM. There is a mechanistic relationship between the stimulation of IL-6 and insulin resistance. IL-6 causes insulin resistance by impairing the phosphorylation of insulin receptor and insulin receptor substrate-1 by inducing the expression of SOCS-3, a potential inhibitor of insulin signaling. In this article, we have briefly described how IL-6 induces the insulin resistance and pathogenesis of T2DM. The prevention of inflammatory disorders by blocking IL-6 and IL-6 signaling may be an effective strategy for the treatment of insulin resistance and T2DM.


Articles with similar content:

Role of Inflammation Amplifier-Induced Growth Factor Expression in the Development of Inflammatory Diseases
Critical Reviews™ in Immunology, Vol.35, 2015, issue 5
Yasunobu Arima, Daisuke Kamimura, Masaaki Murakami, Toru Atsumi, Ikuma Nakagawa
lnterleukin-10 in the Brain
Critical Reviews™ in Immunology, Vol.21, 2001, issue 5
Wen-Hong Shen, Suzanne R. Broussard, Rodney W. Johnson, Robert Dantzer, Klemen Strle, Gregory G. Freund, Keith W. Kelley, Jian-Hua Zhou
Inhibition of STAT3 Activation by RKIP in Colon Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 1
Devasis Chatterjee, Erika L. Moen, Y. Eugene Chin
Role of p53 in Systemic Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
Hirotoshi Kawashima, Hiroshi Nakajima, Hiroaki Takatori, Kotaro Suzuki
Phosphorylation-Based Signaling in Fas Receptor-Mediated Apoptosis
Critical Reviews™ in Immunology, Vol.20, 2000, issue 2
John E. Eriksson, Tim H. Holmstrom